# Multiscale Mechanisms of Exercise-Induced Neuroplasticity: From Molecular Pathways to Network Dynamics and Behavioral Adaptation

**Authors:** Xue Wang, Jun Zhang, Xiaoyu Wang, Shuren Wang, Yidan Zhang, Yupeng Yang, Xuchang Zhou, Chang Liu, Junjie Liu, Mi Zheng

PMC · DOI: 10.3390/brainsci16030294 · 2026-03-06

## TL;DR

Exercise improves brain plasticity through multiple levels, from molecular changes to brain network reorganization, with benefits for cognition and mental health.

## Contribution

This paper integrates multiscale mechanisms of exercise-induced neuroplasticity, emphasizing precision prescriptions for individual variability.

## Key findings

- Exercise activates BDNF signaling and mitochondrial adaptation, enhancing brain function.
- Acute exercise modulates neurochemistry, while chronic exercise promotes structural brain remodeling.
- Personal factors like genetics and environment influence exercise-induced neuroplasticity outcomes.

## Abstract

What are the main findings?
Exercise promotes neuroplasticity through a multiscale mechanism, integrating molecular pathways like BDNF signaling and mitochondrial adaptation with large-scale functional brain network reorganization.Distinct neural mechanisms underlie acute versus chronic exercise, where acute bouts trigger immediate neurochemical modulation while chronic training induces long-term structural remodeling and network homeostasis.

Exercise promotes neuroplasticity through a multiscale mechanism, integrating molecular pathways like BDNF signaling and mitochondrial adaptation with large-scale functional brain network reorganization.

Distinct neural mechanisms underlie acute versus chronic exercise, where acute bouts trigger immediate neurochemical modulation while chronic training induces long-term structural remodeling and network homeostasis.

What are the implications of the main findings?
Physical activity acts as a “multi-target” behavioral intervention capable of enhancing executive function, regulating emotions, and aiding rehabilitation in addiction and neurodegenerative disorders.To maximize therapeutic efficacy, clinical applications should adopt “precision exercise prescriptions” that account for individual variability in genetics, environment, and dose–response relationships.

Physical activity acts as a “multi-target” behavioral intervention capable of enhancing executive function, regulating emotions, and aiding rehabilitation in addiction and neurodegenerative disorders.

To maximize therapeutic efficacy, clinical applications should adopt “precision exercise prescriptions” that account for individual variability in genetics, environment, and dose–response relationships.

Exercise as a non-pharmacological measure is important to increase the brain plasticity hence improving cognitive performance as well as mental health. This narrative review describes in depth the hierarchical multiscale processes of neuroplasticity to exercise, including the presence of neurotrophic factor regulation, cellular metabolic adaptations and neurotransmitter remodeling, up to the structure and functional reorganization of brain networks as seen through neuroimaging, and concluding with adaptive cognitive and behavioral outcomes. We further investigate the role of personal variations in genetic time and social environments in moderating the neuroplasticity of exercise. Furthermore, the review identifies the importance of combining multimodal visualization methods with computational models in generating accurate workout prescriptions and their potential of translation into clinical and educational practice. Lastly, the research problems and “grand challenges” are addressed, with a focus on the importance of exercise as a pleiotropic behavior-intervention and its general implications to the area of promoting brain health.

## Linked entities

- **Proteins:** BDNF (brain derived neurotrophic factor)

## Full-text entities

- **Genes:** SYP (synaptophysin) [NCBI Gene 6855] {aka MRX96, MRXSYP, XLID96}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, HTR1A (5-hydroxytryptamine receptor 1A) [NCBI Gene 3350] {aka 5-HT-1A, 5-HT1A, 5HT1a, ADRB2RL1, ADRBRL1, G-21}, MAP2 (microtubule associated protein 2) [NCBI Gene 4133] {aka MAP-2, MAP2A, MAP2B, MAP2C}, NTF3 (neurotrophin 3) [NCBI Gene 4908] {aka HDNF, NGF-2, NGF2, NT-3, NT3}, GDNF (glial cell derived neurotrophic factor) [NCBI Gene 2668] {aka ATF, ATF1, ATF2, HFB1-GDNF, HSCR3}, GJA1 (gap junction protein alpha 1) [NCBI Gene 2697] {aka AVSD3, CMDR, CX43, EKVP, EKVP3, GJAL}, DLG4 (discs large MAGUK scaffold protein 4) [NCBI Gene 1742] {aka MRD62, PSD95, SAP-90, SAP90}, IGF1 (insulin like growth factor 1) [NCBI Gene 3479] {aka IGF, IGF-I, IGFI, MGF}, PPARGC1A (PPARG coactivator 1 alpha) [NCBI Gene 10891] {aka LEM6, PGC-1(alpha), PGC-1alpha, PGC-1v, PGC1, PGC1A}, NTRK2 (neurotrophic receptor tyrosine kinase 2) [NCBI Gene 4915] {aka DEE58, EIEE58, GP145-TrkB, OBHD, TRKB, trk-B}, PRKAA1 (protein kinase AMP-activated catalytic subunit alpha 1) [NCBI Gene 5562] {aka AMPK, AMPK alpha 1, AMPKa1}, SYN1 (synapsin I) [NCBI Gene 6853] {aka EPILX, EPILX1, MRX50, SYN1a, SYN1b, SYNI}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, GAP43 (growth associated protein 43) [NCBI Gene 2596] {aka B-50, GAP-43, PP46}, SLC6A4 (solute carrier family 6 member 4) [NCBI Gene 6532] {aka 5-HTT, 5-HTTLPR, 5HTT, HTT, OCD1, SERT}, CNR1 (cannabinoid receptor 1) [NCBI Gene 1268] {aka CANN6, CB-R, CB1, CB1A, CB1K5, CB1R}, BDNF (brain derived neurotrophic factor) [NCBI Gene 627] {aka ANON2, BULN2}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, HTR2A (5-hydroxytryptamine receptor 2A) [NCBI Gene 3356] {aka 5-HT2A, HTR2}
- **Diseases:** injury to (MESH:D014947), ischemic stroke (MESH:D002544), addiction to exercise (MESH:D000092202), Infection (MESH:D007239), MCI (MESH:D060825), stroke (MESH:D020521), obese (MESH:D009765), depression (MESH:D003866), peripheral nerve injury (MESH:D059348), cognitive decline (MESH:D003072), PD (MESH:D010300), mood disorders (MESH:D019964), addiction (MESH:D019966), neuroinflammatory (MESH:D000090862), mental disorders (MESH:D001523), addictive behaviors (MESH:D000437), neurodegeneration (MESH:D019636), obsessive-compulsive personality (MESH:D003193), diabetes (MESH:D003920), mitochondrial dysfunction (MESH:D028361), ischemia (MESH:D007511), personality disorders (MESH:D010554), gray matter atrophy (MESH:D002549), overweight (MESH:D050177), withdrawal (MESH:D013375), fatigue (MESH:D005221), chronic pain (MESH:D059350), AD (MESH:D000544), asthma (MESH:D001249), anxiety (MESH:D001007), TBI (MESH:D000070642), COVID-19 (MESH:D000086382)
- **Chemicals:** AEA (-), cortisol (MESH:D006854), fatty acid (MESH:D005227), TCA (MESH:D014233), anandamide (MESH:C078814), adenosine (MESH:D000241), 2-hydroxybutyrate (MESH:C031570), zeaxanthin (MESH:D065146), fumarate (MESH:D005650), 5-HT (MESH:D012701), succinate (MESH:D019802), amino acids (MESH:D000596), lutein (MESH:D014975), endocannabinoids (MESH:D063388), glutamate (MESH:D018698), kynurenine (MESH:D007737), dopamine (MESH:D004298)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13025403/full.md

---
Source: https://tomesphere.com/paper/PMC13025403